KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Cash (2016 - 2025)

Novavax has reported Change in Cash over the past 16 years, most recently at -$27.3 million for Q4 2025.

  • Quarterly results put Change in Cash at -$27.3 million for Q4 2025, up 36.93% from a year ago — trailing twelve months through Dec 2025 was -$289.2 million (down 650.92% YoY), and the annual figure for FY2025 was -$289.2 million, down 650.92%.
  • Change in Cash for Q4 2025 was -$27.3 million at Novavax, down from $14.4 million in the prior quarter.
  • Over the last five years, Change in Cash for NVAX hit a ceiling of $1.4 billion in Q1 2021 and a floor of -$711.9 million in Q1 2023.
  • Median Change in Cash over the past 5 years was -$62.9 million (2023), compared with a mean of -$19.6 million.
  • Biggest five-year swings in Change in Cash: surged 1214.45% in 2021 and later tumbled 1374.87% in 2023.
  • Novavax's Change in Cash stood at -$418.6 million in 2021, then soared by 113.34% to $55.8 million in 2022, then crashed by 247.88% to -$82.6 million in 2023, then soared by 47.55% to -$43.3 million in 2024, then soared by 36.93% to -$27.3 million in 2025.
  • The last three reported values for Change in Cash were -$27.3 million (Q4 2025), $14.4 million (Q3 2025), and -$9.5 million (Q2 2025) per Business Quant data.